View Older Stories
-
Novo Nordisk (NVO) call put ratio 2.5 call to 1 put into quarter results
-
Novo Nordisk (NVO) call put ratio 1.9 calls to 1 put into quarter results
-
Novo Nordisk (NVO) call put ratio 1 call to 1 put into quarter results
-
Novo Nordisk stock tumbles 10% as key trial misses goal
-
Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
-
Novo Nordisk must face fraud lawsuit over CagriSema trial, judge rules
-
Lilly to file for next-gen obesity drug approval in early 2027
-
Novo Nordisk sues Eli Lilly over weight-loss drug ads
-
Novo Nordisk wins EU approval for Wegovy pill and new injection
-
Sandoz submits generic obesity drug applications to FDA
-
Oral Wegovy reaches 33% of total prescriptions by May
-
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
-
Leerink highlights drug demand rebound after Memorial Day
-
Novo Nordisk gets UK approval for daily Wegovy weight loss pill
-
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
-
Novo Nordisk (NVO) call put ratio 2.1 calls to 1 put
-
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
-
TD Cowen raises global GLP-1 sales forecast to $150B by 2030
-
Veru partners with Novo Nordisk for obesity drug combination study
-
Bernstein says this cheap EU pharma stock is "a value trap"
-
Novo Nordisk targets two-thirds cut in drug launch times with AI
-
Novo Nordisk receives EU committee recommendation for oral Wegovy pill
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK200 at Bernstein SocGen Group, 'why's it still a value trap in our view'
-
FDA Commissioner Marty Makary to step down - Politico
-
Novo Nordisk's Wegovy shows 21% weight loss regardless of response speed
-
Novo Nordisk presents data on higher-dose Wegovy weight loss effects
-
TD Cowen on Novo Nordisk (NVO): 'Meet Management Highlights Multiple NearTerm Opportunities'
-
Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy
-
Novo Nordisk Eyes Large-Scale M&A Following Pfizer's Metsera Win - Semafor
-
Novo sees generic Ozempic delayed in China until next year - Bloomberg
-
Novo Nordisk (NVO) Misses Q1 EPS by 33c
-
Novo Nordisk reports Q1 earnings on Wednesday: Analysts flag key focus topics
-
Novo Nordisk (NVO) call put ratio 2.3 calls to 1 put with a focus on May 8 weekly options into quarter results
-
Novo Nordisk (NVO) call put ratio 3.4 calls to 1 put with a focus on September 35 calls into quarter results
-
Why Eli Lilly stock is down 3% today: FDA adverse event data explained
-
Novo Nordisk rebrands diabetes tablet as Ozempic in US
-
Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
-
FDA proposes to exclude semaglutide, tirzepatide from compounding list
-
Novo Nordisk gets FDA fast track status for ATTR heart disease drug
-
Morgan Stanley Comments on Eli Lilly (LLY) Amid Premarket Volatility
-
Hims & Hers expands platform to include Eli Lilly weight loss medications
-
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
-
Eli Lilly and Novo Nordisk shares fall as CVS opts out of Medicare obesity drug coverage
-
CVS Health Opts Out Of Medicare Obesity Drug Coverage Model
-
Walmart expands weight management services with virtual care platform
-
Novo Nordisk (NVO) PT Lowered to $36 at BMO Capital
-
Novo Nordisk launches higher-dose Wegovy for weight management
-
Novo Nordisk repurchases 805,000 B shares worth DKK 186.5 million
-
Novo Nordisk says Wegovy pill shows greater weight loss than Lilly rival
-
Novo Nordisk (NVO) call put ratio 1.2 calls to 1 put

